Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
about
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus ChallengeSingle-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitorThe Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like DomainsOrthopox Viruses: Infections in HumansTherapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201)The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors.Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections.Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.Smallpox vaccine safety is dependent on T cells and not B cellsEpidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunityEnhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless miceEvaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.Variola virus-specific diagnostic assays: characterization, sensitivity, and specificity.Development of ST-246® for Treatment of Poxvirus Infections.Variola virus F1L is a Bcl-2-like protein that unlike its vaccinia virus counterpart inhibits apoptosis independent of Bim.Pathogen-specific recombinant human polyclonal antibodies: biodefence applications.Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.Smallpox antiviral drug development: satisfying the animal efficacy rule.Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virusLow-resolution structure of vaccinia virus DNA replication machineryL1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccinesTherapeutic and prophylactic drugs to treat orthopoxvirus infectionsUsing biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.Orthopoxvirus targets for the development of new antiviral agents.Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus.Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.Vaccinia virus infection modulates the hematopoietic cell compartments in the bone marrow.Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides.
P2860
Q24535956-55A6952C-EF51-4DA2-9D87-E35B2B307ED0Q24656105-9531A31C-26D8-47D4-839C-7B941923EB49Q27658759-F6ED39B7-C3F9-4312-9CD0-8BEA4BB2B6F2Q28742218-7207F26B-A51C-416E-9E9A-C4AF5CC973ABQ28743894-315024F6-FF58-4B50-8968-4A7AE636C21BQ30223108-8D300216-547D-4FE8-8868-FF1A9EE7A2A0Q33570349-0626CFE3-1235-4176-A5DE-F5D109B04B66Q33792207-EB12585A-0037-43E1-AE31-0A92C9F6A468Q33876688-1C4D1695-1D0A-42E6-86D8-B2D815F6245BQ33883711-AD8790CC-5285-4E8B-8911-651D347E1FE9Q34140816-6C86B2CA-E210-4D12-971B-66702CA43989Q34289866-B13C442C-91A6-4256-B0EA-CD3BF793C242Q34510424-6454D70C-8061-47AB-A9D6-620F66C09B3FQ34714569-0935C676-F844-4D1F-B320-75ACAA1D392AQ34743303-9AC9F3DE-4052-4ED2-BF5A-98350D4718FFQ34762818-0101DDB3-D5EF-41C7-A48B-06AA4CE2997CQ34922842-554635C8-A44E-4F4A-BAC7-5E43222392E8Q35007525-73D89D89-2AB8-4FF1-A1D8-4D153D11AFD3Q35193137-25D62D05-EEB7-4606-8698-1F00F01B511EQ35260385-19CD20CB-3E3D-4D0B-9025-297922ECA32CQ35274610-34F8E0B8-03B8-4DF4-87D1-01425BE3664FQ35684876-C850B5CF-5EC5-4156-AF66-5FABD32EC459Q35759004-8A2B013F-5E50-457D-B67C-893D4E2FBF31Q36172531-3A30D2E7-ACBC-4FC3-A549-A9EFC2773EB0Q36441506-BCF2C13A-584A-4A4C-87C6-C64CD51BE321Q36499021-5CA7E04C-39EF-43F7-9088-4A7305E63268Q36559777-F11F81B1-1462-4022-94D5-27BC682924D6Q36798711-053A559B-7E57-450B-8C0B-61C99C244580Q37009973-EB35072A-D991-4BBB-847D-DC46034A22F2Q37062384-721A120A-A987-4285-AE88-9274C161FC09Q37173398-6CCAA331-44B9-4BC4-8494-40CA18206CDDQ37332861-0ED585E0-EA9C-4FA3-8937-C819AEB00A65Q37461110-6D4CAD2F-AD61-4ACD-910F-D74FA59D1A44Q37593480-03CE8A08-766E-425F-9DF9-1171FB256ED0Q37734396-38FB34B5-AEF1-42F7-8EEA-E957D0DCA12AQ39706186-3DC7BDBE-D787-41DB-B21C-9E0DEEDAB13CQ41361126-9EA3E534-CA64-414B-9008-52B6630EF382Q42926021-D77F5142-8FED-4560-9AB0-241779E48248Q42974816-581B2729-1B05-4122-8845-21B444EAEA5EQ44813635-F60153BC-6EEC-46E1-ACC5-A4C1FEDDCBBB
P2860
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
@ast
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
@en
type
label
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
@ast
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
@en
prefLabel
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
@ast
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
@en
P1433
P1476
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination.
@en
P2093
P304
P356
10.1016/S0166-3542(03)00008-1
P577
2003-04-01T00:00:00Z